Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries (“TBIs”), both concussions and penetrating injuries,...
Many forget to take daily pills, experimental injectable drugs last longer Researchers at the University of Colorado Anschutz Medical Campus, working with the National Institutes of Health, will conduct a clinical trial beginning this month to determine if monthly...
MRI-guided imaging helps team identify amyloid buildup that is then targeted with focused ultrasound Vibhor Krishna, M.D., (right) fits David Shorr with a helmet-like device used in a new clinical trial for Alzheimer’s disease at The Ohio State University Wexner...
Cohort two fully enrolled in a wide range of cancer types Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today...
Neuropore Therapies, Inc. announced today that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of NPT520-34. NPT520-34 is an orally bioavailable,...
ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced initiation of...
Email
Text